Avance Clinical

Avance Clinical is a full-service Contract Research Organisation (CRO) headquartered in Adelaide, Australia, with extensive global operations spanning North America, Asia, New Zealand, and Europe. With more than 30 years of clinical operations experience, the company specialises in guiding biotechs through the complete drug development journey, from preclinical consultation and early-phase trials through to late-phase multi-regional studies. Avance Clinical leverages proprietary processes including ClinicReady for preclinical foundations and GlobalReady for seamless phase progression, whilst maintaining an expert team of over 330 CRO specialists delivering world-class clinical operations, data management, biostatistics, medical writing, quality assurance, patient recruitment, and global scientific and regulatory affairs support.

Avance Clinical's therapeutic expertise spans over 250 indications across all therapeutic areas, with particular specialisation in oncology, central nervous system (CNS) disorders, rare diseases and orphan drugs, infectious diseases, dermatology, endocrinology, ophthalmology, and respiratory and allergy conditions. The company's late-phase operations deliver multi-regional clinical excellence, leveraging the latest technology including artificial intelligence, real-world data and evidence, and gold-standard systems and processes across all functional areas. Avance Clinical maintains in-house global regulatory affairs teams, certified platform specialists including Medidata-trained experts, and delivers data consistently recognised by key global regulators including the TGA, FDA, EMA, MHRA, MFDS, and PDMA.

Avance Clinical operates from its global headquarters in Adelaide and maintains a North American headquarters in Wake Forest, North Carolina, with expanding operational footprints across Singapore, Malaysia, mainland China, and India. The company differentiates itself through personalised, customised solutions tailored to each client rather than one-size-fits-all approaches. Key competitive advantages include rapid Australian start-up capabilities with Site Initiation Visits and study commencement achievable within five to six weeks, no IND requirement for Australian trials, and access to the 43.5 per cent Australian research and development tax rebate programme. Over 280 Phase III global trials have conducted Phase I studies in Australia through Avance Clinical, and the company has completed over 500 studies in the past five years whilst engaging more than 18,000 trial participants.